ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.460
+0.120 (2.76%)
At close: Mar 27, 2026

HKG:1541 Ratios and Metrics

Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,9252,5162,10211,187--
Market Cap Growth
-15.78%19.70%-81.21%---
Enterprise Value
1,0461,9121,65510,650--
Last Close Price
4.465.835.1629.90--
PS Ratio
11.2114.6524.831319.67--
PB Ratio
2.192.862.9113.57--
P/TBV Ratio
2.192.862.9113.57--
EV/Sales Ratio
6.0911.1419.561256.23--
Debt / Equity Ratio
0.290.290.200.100.02-0.01
Net Debt / Equity Ratio
-1.00-1.00-0.91-0.71-0.800.41
Net Debt / EBITDA Ratio
3.703.702.071.521.763.21
Net Debt / FCF Ratio
--4.451.442.372.81
Asset Turnover
0.150.150.090.010.01-
Quick Ratio
3.693.693.515.2612.300.27
Current Ratio
3.843.844.045.9312.600.28
Return on Equity (ROE)
-29.87%-29.87%-44.38%-49.68%--
Return on Assets (ROA)
-13.80%-13.80%-21.43%-26.59%-26.29%-
Return on Capital Employed (ROCE)
-27.10%-27.10%-43.50%-48.10%-46.20%13.30%
Earnings Yield
-12.64%-9.67%-15.99%-3.74%--
FCF Yield
---7.01%-3.65%--
Buyback Yield / Dilution
-9.35%-9.35%-4.24%-9.05%-284.99%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.